All News

laptop image

Insights into Treating Lupus - A Rheum Survey 

Jack Cush, MD

RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed the survey.

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

ICYMI: B Cells at the Brink in Sjögren Disease

Jack Cush, MD

A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.

Read Article
RA.vascular.cholesterol.plaque.jpg

EULAR26: Updates in SLE and APS

EurekAlert!

Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.

Read Article
B CELL DEPLETION

B cell Targeting in SLE

MedPage Today

Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.

Read Article
CAR-T

CAR-T Cell Therapies at EULAR 2026

EurekAlert!

In an oral abstract presentation on Wednesday 3rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-citrullin

Read Article
Vaccine2.jpg (keep)

EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases

Jack Cush, MD

This update includes new pandemic era evidence, recombinant zoster vaccine data, and new perspectives on vaccination in patients taking novel immunosuppressants. Five overarching principles and 10 vaccine recommendations follow.

Read Article
Eular stage

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc

Read Article
Eular stage

From BiTE to TriTE: Progress of T-cell Engagers in RMDs

Md Yuzaiful Md Yusof, MRCP(UK), PhD

The EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs).

Read Article
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026

Dr. John Cush RheumNow ( View Tweet)

Obexelimab in IgG4-Related Disease: INDIGO Trial Dr. Henrique Dalmolin reports on abstract OP018 from EULAR 2026. https://t.co/Wid9ZzESae https://t.co/Qo4y8ebkOn

Links:

Dr. John Cush RheumNow ( View Tweet)
B cell Targeting in SLE Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest. https://t.co/wGaZPnXfID https://t.co/a0fNvdcrbQ

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY> Do you prefer a lupus drug if it has a lupus nephritis indication (when your treating non-renal SLE)? Answer here >> https://t.co/1KridYM9n8 https://t.co/zIqNB5Mc0O

Links:

Dr. John Cush RheumNow ( View Tweet)
Missed a session at EULAR 2026? No problem. The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/YZ7oRNXfqU
Dr. John Cush RheumNow ( View Tweet)
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/AFnsmEYj41
Dr. John Cush RheumNow ( View Tweet)
Missed a session at EULAR 2026? No problem. The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/cKmhq8mAIf
Dr. John Cush RheumNow ( View Tweet)
The North American Expert Consensus on ASCVD Screening in Lupus Nephritis Drs. Sheila Reyes and Shivani Garg discuss abstract OP094, presented in London at the EULAR 2026 Congress https://t.co/Vm2QFlO3fL https://t.co/4Xp9tkubLh

Links:

Dr. John Cush RheumNow ( View Tweet)
Usual testing for SSA (Ro) pos. in Sjogrens identifies both Ro52 + Ro60 Abs, found in 70% of SjD. Pts who are double pos (Ro52+Ro60) have more severe dz, more Bcell activity. Ro60+ have milder dz; Recent report shows SjD pts have Ro60-specific CD4 T cells, activating Bcells https://t.co/SqoLICHOkS
Dr. John Cush RheumNow ( View Tweet)
Prevalence of GI involvement in dermatomyositis (DM) was assessed in 2 cohorts (n = 167). Severe GI involvement seen in 18% NXP2+ & 6% MDA5+; more common w/ NXP2 than other DM (HR 8.85). NXP2 w/ severe GI dz were younger, facial edema @dx w/ both skin & muscle dz activity. https://t.co/5kNvAkTLc0
Dr. John Cush RheumNow ( View Tweet)
From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/o8Tn77aYRg
Dr. John Cush RheumNow ( View Tweet)
LLMs in SLE: From Patient Education to Clinical Decision Support The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical https://t.co/0rhada36Ji
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×